Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?

By Chim Lesley   Kelly Patrick J.   Salkeld Glenn   Stockler Martin R.  

PharmacoEconomics, Vol. 28, Iss. 6, 2010-06 ,pp. : 463-475

Adis International

Access to resources Recommend Favorite

Newly-licensed drugs recommended by Scottish Medicines Consortium

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 418, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Economic Model of First-Line Drug Strategies to Achieve Recommended Glycaemic Control in Newly Diagnosed Type 2 Diabetes Mellitus

By Ramsdell J.W.  

PharmacoEconomics, Vol. 21, Iss. 11, 2003-01 ,pp. : 819-837

Adis International

Access to resources Recommend Favorite

Effectiveness of Guideline-Recommended Cardiac Drugs for Reducing Mortality in the Elderly Medicare Heart Failure Population: A Retrospective, Survey-Weighted, Cohort Analysis

By Richardson Diane M.  

Drugs & Aging, Vol. 27, Iss. 10, 2010-10 ,pp. : 845-854

Adis International

Access to resources Recommend Favorite

Drugs, Heart Failure and Quality of Life: What Are We Achieving? What Should We Be Trying to Achieve?

By Doba N.   Tomiyama H.   Nakayama T.  

Drugs & Aging, Vol. 14, Iss. 3, 1999-03 ,pp. : 153-163

Adis International

Access to resources Recommend Favorite